Ignite Creation Date:
2024-05-06 @ 10:15 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03204734
Status:
UNKNOWN
Last Update Posted:
2017-07-02
First Post:
2017-06-24
Brief Title:
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Organization Data
Organization:
Zhejiang Cancer Hospital
Class:
OTHER
Study ID:
ZJCH15009
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Zhejiang Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Zhengyabing
Responsible Party Title:
Chief Physician
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Zhejiang Cancer Hospital
Old Name:
None
Old Organization:
None